NEW YORK (GenomeWeb) – A new study this week by Trovagene and its academic collaborators is the first to demonstrate the validity of the company's liquid biopsy strategy for detecting EGFR mutations in both blood and urine of patients with lung cancer.

The paper, published online in the Journal of Thoracic Oncology this week, is an important step for Trovagene toward broadening adoption if its tests beyond what is currently a relatively small corps of early adopters, company officials told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.